Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,640,868
  • Shares Outstanding, K 86,154
  • Annual Sales, $ 212,960 K
  • Annual Income, $ -86,420 K
  • 60-Month Beta 1.75
  • Price/Sales 17.10
  • Price/Cash Flow N/A
  • Price/Book 7.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.27
  • Number of Estimates 5
  • High Estimate 0.46
  • Low Estimate -0.65
  • Prior Year -0.28
  • Growth Rate Est. (year over year) +3.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.74 +21.65%
on 05/28/19
45.74 -7.61%
on 06/20/19
+6.69 (+18.81%)
since 05/24/19
3-Month
33.51 +26.11%
on 05/10/19
55.71 -24.14%
on 04/01/19
-12.18 (-22.37%)
since 03/26/19
52-Week
33.51 +26.11%
on 05/10/19
68.55 -38.35%
on 07/09/18
-19.09 (-31.12%)
since 06/26/18

Most Recent Stories

More News
FibroGen to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced that Chief Executive Officer Thomas B. Neff will...

FGEN : 42.26 (-0.02%)
FibroGen Appoints Suzanne Blaug to Board of Directors

FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today announced the appointment of Suzanne Blaug as an independent...

FGEN : 42.26 (-0.02%)
First Week of FGEN July 19th Options Trading

Investors in FibroGen Inc saw new options become available this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FGEN options chain for...

FGEN : 42.26 (-0.02%)
Westleaf Selected for Manitoba Cannabis Store Licence

Opportunity to build retail store and online sales expands distribution footprint

WSLFF : 0.4143 (+3.57%)
GNCA : 4.03 (+14.81%)
EYEG : 0.24 (unch)
FGEN : 42.26 (-0.02%)
FATE : 19.52 (-1.01%)
WL.VN : 0.550 (+5.77%)
Implied Volatility Surging for FibroGen (FGEN) Stock Options

Investors need to pay close attention to FibroGen (FGEN) stock based on the movements in the options market lately.

FGEN : 42.26 (-0.02%)
Fibrogen Inc Rises 3.10% on Heavy Volume: Watch For Potential Pullback

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $38.62 to a high of $38.95. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $38.20...

FGEN : 42.26 (-0.02%)
32.9% Return Seen to Date on SmarTrend Fibrogen Inc Call (FGEN)

SmarTrend identified a Downtrend for Fibrogen Inc (NASDAQ:FGEN) on March 8th, 2019 at $54.15. In approximately 2 months, Fibrogen Inc has returned 32.90% as of today's recent price of $36.34.

FGEN : 42.26 (-0.02%)
FibroGen INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In FibroGen, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ:FGEN).

FGEN : 42.26 (-0.02%)
Look for Shares of Fibrogen Inc to Potentially Rebound after Yesterday's 24.13% Sell Off

Fibrogen Inc (NASDAQ:FGEN) traded in a range yesterday that spanned from a low of $34.65 to a high of $37.91. Yesterday, the shares fell 24.1%, which took the trading range below the 3-day low of $45.19...

FGEN : 42.26 (-0.02%)
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of 22.06% and 19.32%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

FGEN : 42.26 (-0.02%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade FGEN with:

Business Summary

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development...

See More

Key Turning Points

2nd Resistance Point 43.33
1st Resistance Point 42.79
Last Price 42.26
1st Support Level 41.83
2nd Support Level 41.41

See More

52-Week High 68.55
Fibonacci 61.8% 55.16
Fibonacci 50% 51.03
Fibonacci 38.2% 46.90
Last Price 42.26
52-Week Low 33.51

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar